NASDAQ: CASI | 中文 | Contact Us


The Company acquired exclusive China rights for the development and distribution of a novel formulation of Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. Thiotepa has a long history of established use in the hematology/oncology setting.

Clinical Development Status

CASI intends to advance the development, import drug registration, and market approval of this product in China, and expects the registration study to be initiated in 2021.

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More